Literature DB >> 10981205

Measuring the impact of onychomycosis on patient quality of life.

R R Turner1, M A Testa.   

Abstract

According to survey research, onychomycosis, a fungal infection of the toenail or fingernail, affects quality of life including physical and social functioning and emotional health. We developed an onychomycosis disease-specific questionnaire (ODSQ) that sensitively assessed symptom distress, functional impact, and social stigma associated with the disease. Samples of patients enrolled in a randomized controlled clinical trial were used for the psychometric evaluations. The multi-item scales were internally consistent (alpha > or = 0.80) and reproducible (ICC > 0.85). Interscale correlations between the ODSQ and generic scales were moderate and consistent with the hypothesized magnitude and directions. Construct validation, employing known groups analysis, supported the hypothesized impact of onychomycosis on three domains of quality of life: physical functioning, emotional health, and social functioning. Significant differences were found between clinically "cured", "improved", or "failed" patients, and between mycologically "eradicated" and "persistent" patients. The ODSQ was responsive to clinical change and more sensitive than derived Medical Outcomes Study Short Form-36 scales. The ODSQ provides reliable, validated and responsive information about the consequences of onychomycosis and its treatment.

Entities:  

Mesh:

Year:  2000        PMID: 10981205     DOI: 10.1023/a:1008986826756

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  11 in total

Review 1.  Impact of onychomycosis on quality of life.

Authors:  L A Drake
Journal:  J Am Podiatr Med Assoc       Date:  1997-11

2.  Effect of onychomycosis on quality of life.

Authors:  L A Drake; R K Scher; E B Smith; G A Faich; S L Smith; J J Hong; M J Stiller
Journal:  J Am Acad Dermatol       Date:  1998-05       Impact factor: 11.527

3.  The effect of toenail onychomycosis on patient quality of life.

Authors:  B E Elewski
Journal:  Int J Dermatol       Date:  1997-10       Impact factor: 2.736

4.  Assessment of quality-of-life outcomes.

Authors:  M A Testa; D C Simonson
Journal:  N Engl J Med       Date:  1996-03-28       Impact factor: 91.245

5.  Onychomycosis: a significant medical disorder.

Authors:  R K Scher
Journal:  J Am Acad Dermatol       Date:  1996-09       Impact factor: 11.527

Review 6.  Diagnosing and treating onychomycosis.

Authors:  N Zaias; B Glick; G Rebell
Journal:  J Fam Pract       Date:  1996-05       Impact factor: 0.493

7.  Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial.

Authors:  M A Testa; D C Simonson
Journal:  JAMA       Date:  1998-11-04       Impact factor: 56.272

8.  Valuing quality of life and improvements in glycemic control in people with type 2 diabetes.

Authors:  M A Testa; D C Simonson; R R Turner
Journal:  Diabetes Care       Date:  1998-12       Impact factor: 19.112

9.  Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group.

Authors:  M A Testa; R B Anderson; J F Nackley; N K Hollenberg
Journal:  N Engl J Med       Date:  1993-04-01       Impact factor: 91.245

10.  Quality of life of persons with onychomycosis.

Authors:  D P Lubeck; D L Patrick; P McNulty; S K Fifer; J Birnbaum
Journal:  Qual Life Res       Date:  1993-10       Impact factor: 4.147

View more
  10 in total

1.  In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes.

Authors:  M Ghannoum; N Isham; L Long
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

Review 2.  Patient-Reported Outcomes in Onychomycosis: A Review of Psychometrically Evaluated Instruments in Assessing Treatment Effectiveness.

Authors:  Jenny Wang; Lauren E Wiznia; Evan A Rieder
Journal:  Skin Appendage Disord       Date:  2017-04-21

Review 3.  Onychomycosis: health-related quality of life considerations.

Authors:  James W Shaw; Vijay N Joish; Stephen Joel Coons
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Ciclopirox Hydroxypropyl Chitosan (CPX-HPCH) Nail Lacquer and Breathable Cosmetic Nail Polish: In Vitro Evaluation of Drug Transungual Permeation Following the Combined Application.

Authors:  Daniela Monti; Silvia Tampucci; Valentina Paganini; Susi Burgalassi; Patrizia Chetoni; Jordi Galván; Francesco Celandroni; Emilia Ghelardi
Journal:  Life (Basel)       Date:  2022-05-27

5.  Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life.

Authors:  Antonella Tosti; Bom E Elewski
Journal:  J Clin Aesthet Dermatol       Date:  2014-11

6.  Onychodystrophy and its management.

Authors:  Tilmann Oppel; Hans Christian Korting
Journal:  Ger Med Sci       Date:  2003-07-01

7.  A preformulation strategy for the selection of penetration enhancers for a transungual formulation.

Authors:  Biji Palliyil; David B Lebo; Pankil R Patel
Journal:  AAPS PharmSciTech       Date:  2013-04-10       Impact factor: 3.246

Review 8.  The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature.

Authors:  Aditya K Gupta; Rachel R Mays
Journal:  Skin Appendage Disord       Date:  2018-02-13

9.  Enhanced Enzymatic Activity of Yeast-like Fungi Responsible for Onychomycosis in Renal Transplant Recipients.

Authors:  Jolanta Weglowska; Adam Reich; Bronisława Walów; Jacek C Szepietowski
Journal:  Int J Biomed Sci       Date:  2006-02

10.  Psychosocial perception of adults with onychomycosis: a blinded, controlled comparison of 1,017 adult Hong Kong residents with or without onychomycosis.

Authors:  Henry Hl Chan; Emma T Wong; Chi Keung Yeung
Journal:  Biopsychosoc Med       Date:  2014-07-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.